

Practical Clinical Toxicology

Toxicity of Digitalis Glycosides

Lab. 6

5th Year

2018-2019

University of Mustansiriyah/College of Pharmacy

Department of Pharmacology & Toxicology

Lecturer Rua Abbas Al-Hamdy



Introduction:

- Digitalis glycosides are life-saving drugs when used in therapeutic doses in the treatment of congestive heart failure (CHF), & for management of certain supraventricular arrhythmia.
- Digoxin is the one of the most widely prescribed drugs.
- Digoxin acts through inhibition of the Na^+/K^+ -adenosine triphosphatase (ATPase) enzyme as shown in figure 1.




Figure 1. Mechanism of action of digoxin. ATPase = adenosine triphosphatase.

- It is estimated that 20-30% of patients taking a digitalis preparation will experience toxicity because the drugs have an extremely narrow therapeutic index.
- The serum concentration of digoxin for therapeutic activity is in the normal range of 1.2-1.7 ng/mL & clinically significant toxicity usually occurs with concentrations 2-3 times higher.
- The mortality rate with toxic dose is reported to be as great as 25%.

Factors that increase the risk of toxicity to digitalis glycosides:

- Concurrent administration of a diuretic that induces potassium loss is reported to be the most frequent cause of toxicity.
- Individuals with *Eubacterium lentum* in their colon may require larger doses of digitalis to achieve the desired therapeutic serum concentrations. This microorganism reduces the lactone ring of digitalis. Digitalis blood concentrations may become toxic when these patients receive antibiotics, such as tetracycline or erythromycin, which eradicate the organism.

- Since 60-80% of digoxin is excreted through the kidneys as shown in table 1, decreased renal excretion would result in accumulation of digoxin & toxicity.
- Interactions with other drugs such as verapamil & quinidine (they cause increase in plasma concentration of digoxin probably by digoxin displacement from tissue-binding sites),
- Hypokalemia, &
- Hypothyroidism.

Table 1 Pharmacology of Selected Cardioactive Steroids

Pharmacology	Digoxin	Digitoxin
Onset of Action		
PO	1.5–6 h	3–6 h
IV	5–30 min	30 min–2 h
Maximal effect		
PO	4–6 h	6–12 h
IV	1.5–3 h	4–8 h
Intestinal absorption	40%–90% (mean, 75%)	>95%
Plasma protein binding	25%	97%
Volume of distribution	5–7 L/kg (adults) 16 L/kg (infants) 10 L/kg (neonates) 4–5 L/kg (adults with renal failure)	0.6 L/kg (adults)
Elimination half-life	1.6 days	6–7 days
Route of elimination	Renal (60%–80%), with limited hepatic metabolism	Hepatic metabolism (80%)
Enterohepatic circulation	7%	26%

Characteristics of poisoning:

- Early manifestations of intoxication that occur in approximately 50% of all cases generally involve the gastrointestinal tract.

Anorexia, nausea, vomiting, & abdominal pain are common.

Nausea & vomiting occur from direct drug action on the chemoreceptor trigger zone (CTZ).

- Blurred vision, loss of visual acuity, & green yellow halos have been described as early-appearing symptoms.
- CNS effects include a variety of neuropsychiatric disturbances.
- Digitalis intoxication can provoke a large number of arrhythmias. These include bradyarrhythmias or tachyarrhythmias, or a combination of both.

Management of poisoning:

- Management of acute digitalis toxicity involves removal of ingested drug, maintenance of a normal potassium concentration, reversal of arrhythmias, & the use of a specific antidote (digoxin immune Fab).
- Gastric lavage should be performed to remove the unabsorbed drug, although vomiting may already have accomplished this.
- Repeated administration of activated charcoal or cholestyramine is recommended to enhance elimination of the glycoside by interrupting the entero-hepatic cycling exhibited by digitoxin, & possibly digoxin.

- Hyperkalemia (5.5-13.5 mEq/L) is caused by acute digitalis toxicity, while hypokalemia is more common with chronic digitalis use.
- Hyperkalemia may require treatment with insulin plus glucose, & sodium bicarbonate.
- If hypokalemia is encountered with tachy- or bradyarrhythmias, continuous potassium replacement alone may be sufficient.
- For atrial & ventricular arrhythmias that do not respond to potassium therapy, the treatment of choice includes phenytoin & lidocaine.

- Potassium administration in a person with digitalis-induced hyperkalemia can result in heart block.
- If digitalis has produced atrioventricular (AV) block, atropine is given to produce vagolytic effect to increase the heart rate & AV conduction.
- β -blockers, such as propranolol, are useful to suppress supraventricular & ventricular arrhythmias but may depress the sinoatrial (SA) node & AV conduction especially in a patient with an already failing heart, that limiting their usefulness.

- Because digoxin has a large volume of distribution, hemodialysis is not a successful method to enhance elimination of digoxin. However, hemodialysis is still sometimes required.....why?

Digoxin Immune Fab (Digibind):

- ❖ Digoxin immune Fab is used as an antidote reserved for life-threatening overdoses.
- ❖ Indications of such toxicity include:
 - ingestion of more than 10 mg of digoxin by healthy adults or 4 mg by children,
 - Steady-state serum concentrations greater than 10 ng/mL; or
 - if blood potassium concentration exceeds 5 mEq/L.

- ❖ Dosage of digibind can be calculated according to the amount of digoxin or digitoxin in the patient's body.
- ❖ When steady-state serum concentrations of digoxin or digitoxin is known, the total body load can be estimated as shown below:

$$\text{Body load(mg)} = \frac{(\text{SDC})(\text{mean Vd})(\text{wt in Kg})}{1000}$$

SDC is the serum digitalis concentration in ng/mL.

Vd: volume of distribution

Vd of digoxin = 5.6 L/kg

Vd of digitoxin = 0.56 L/kg

- ❖ Each vial of antidote contains 40 mg of digibind. This will bind 0.6 mg digoxin or digitoxin.
- ❖ The total number of vials needed can be obtained by dividing the total body load of drug in mg, by 0.6 mg/vial.
- ❖ Adverse effects to digibind have been minimal including sensitivity, erythema at the site of injection, rash, & urticaria have been reported.

How many milligrams of digoxin-specific antibody fragment are required to treat a 40 years old male patient, weighing 70 kg in whom digoxin assay revealed a serum concentration of 0.015 $\mu\text{g}/\text{mL}$?

$$\text{Body load (mg)} = \frac{(\text{SDC})(\text{mean Vd})(\text{wt in Kg})}{1000}$$

Serum digitalis concentration in ng/mL = 15

Vd of digoxin = 5.6 L/kg

Body load = $15 \times 5.6 \times 70 / 1000 = 5.88$ mg of digoxin.

Each vial of digibind contains 40 mg

40 mg of digibind would bind 0.6 mg of digoxin

$$\frac{40 \text{ mg (digibind)}}{0.6 \text{ mg (digoxin)}} = \frac{x \text{ (digibind)}}{5.88 \text{ mg}}$$

X = 392 mg of digibind

$$\frac{392 \text{ mg}}{40 \text{ mg/vial}} = 9.8 \text{ which means 10 vials}$$

Case study:

A 65-year-old woman was admitted to an emergency department after ingestion of seventy 0.0625-mg tablets of digoxin (4.375 mg total) in a suicide attempt, 5 hr previously. Her medical history revealed rheumatic fever and analgesic nephropathy. Usual therapy included digoxin 0.0625 mg/day.

She underwent lavage and received a slurry of activated charcoal via a nasogastric tube. Laboratory values included serum potassium, 4.3 mmol/L; serum creatinine, 395 μ mol/L; and serum digoxin, 19.8 mmol/L. Blood pressure was 135/85 mm Hg. Heart rate was 130 beats/min & irregular.

The patient was alert. She was nauseated & vomited several times. Her vision was blurred.

An electrocardiogram revealed atrial & junctional tachycardia with intermittent block, & occasional ventricular ectopic beats. After several hours, her serum potassium concentration was 5.0 mmol/L.

Treatment included phenytoin 500 mg. she did not respond to therapy. By now her serum potassium concentration had risen to 5.4 mEq/L. Vitals remained unchanged. She was then given 400 mg of digoxin immune Fab over 30 min. Her ECG remained unaltered, so another 400 mg dose of the antidote was administered 1 hr later.

One hour after the second dose, her ECG showed a sinus rhythm of 110 beats/min. Serum potassium concentration had returned to 4.5 mEq/L. She maintained a sinus rhythm & her heart rate stabilized at 90 beats/min over the next 4 hr.

Notes:

Normal serum potassium level 3.5-5 mEq/L

Normal serum creatinine in women 45-90 $\mu\text{mol/L}$

*Thank
you*

